Redeye retains its positive view on Sdiptech following a slightly stronger Q4 report than expected. Although boosted by some caught-up orders, organic growth remains solid, and Sdiptech’s operations continue to do well. We leave our forecasts mainly unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/